Table 1 Study Population Characteristics at Diagnosis of Non-Metastatic Breast Cancer (N = 13,434 women diagnosed at Kaiser Permanente Northern California, 2005–2015)1
From: Metabolic abnormalities and survival among patients with non-metastatic breast cancer
Age at diagnosis (years) | 62.34 (11.81) |
|---|---|
Race/ethnicity | |
White | 8,949 (67%) |
Black | 981 (7.3%) |
Asian/Pacific Islander | 2,363 (18%) |
Hispanic/Latino | 999 (7.4%) |
Other | 131 (1.0%) |
Missing | 11 (< 0.1%) |
Body Mass Index Category | |
Underweight (< 18.5 kg/m2) | 136 (1%) |
Normal (18.5—< 25 kg/m2) | 3,592 (26.7%) |
Overweight (25—< 30 kg/m2) | 4,247 (32%) |
Class 1 Obesity (30—< 35 kg/m2) | 2,689 (20%) |
Class 2/3 Obesity (≥ 35 kg/m2) | 2,193 (16%) |
Missing | 577 (4.3%) |
Diabetes | 2,438 (18%) |
Overall mortality | 2,876 (21%) |
Breast cancer mortality | 1,080 (8.0%) |
ER positive | 11,164 (83%) |
PR positive | 8,686 (65%) |
HER2 positive | 1,339 (10.0%) |
Stage at diagnosis | |
1 | 7,786 (58%) |
2 | 4,420 (33%) |
3 | 1,228 (9.1%) |
Surgery | 13,142 (98%) |
Radiation | 4,789 (36%) |
Chemotherapy | 5,362 (40%) |
Medications | |
Anti-hypertensives | 7,681 (57%) |
Statins | 5,299 (39%) |
Other dyslipidemia medication | 514 (3.8%) |
Glucose | |
Normal (60—99 mg/dL) | 7,828 (58%) |
Low (< 60 mg/dL) | 6 (< 0.1%) |
High (> 99 mg/dL) | 5,600 (42%) |
High Density Lipoprotein (LDL) Cholesterol | |
Normal (> 45 mg/dL) | 10,663 (79%) |
Low (≤ 45 mg/dL) | 2,771 (21%) |
Low Density Lipoprotein (LDL) Cholesterol | |
Normal (< 129 mg/dL) | 9,251 (69%) |
High (≥ 129 mg/dL) | 4,183 (31%) |
Triglycerides | |
Normal (< 199 mg/dL) | 11,494 (86%) |
High (≥ 199 mg/dL) | 1,940 (14%) |